The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: Number or stage

Journal of Clinical Pathology

Volumn 65, Issue 7, 2012, Pages 624-630

  Rakha, Emad A ^a   Morgan, David ^b   Macmillan, Douglas ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER SPECIFIC SURVIVAL; BREAST CARCINOMA; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; LYMPH NODES; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84863573723     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200755     Document Type: Article

References (42)

1. WHO classification of Tumours. Pathology and genetics. In: Tavassoli FA, Devilee P, eds. Tumours of the Breast and Female Genital Organs. Lyon: IARC press, 2003.
2. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008;26:3153-8.
3. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
4. Wilking N, Rutqvist LE, Carstensen J, et al. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Stockholm Breast Cancer Study Group. Acta Oncol 1992;31:29-35.
5. Fisher ER, Anderson S, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 1993;71:2507-14. (Pubitemid 23100484)
6. Russo J, Frederick J, Ownby HE, et al. Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol 1987;88:123e31.
7. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-19.
8. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 1999;31:209-23. (Pubitemid 29424143)
9. Balslev I, Axelsson CK, Zedeler K, et al. The Nottingham prognostic Index applied to 9,149 patients from the studies of the Danish breast cancer Cooperative group (DBCG). Breast Cancer Res Treat 1994;32:281-90. (Pubitemid 24351375)
10. D'Eredita G, Giardina C, Martellotta M, et al. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001;37:591-6. (Pubitemid 32261016)
11. Okugawa H, Yamamoto D, Uemura Y, et al. Prognostic factors in breast cancer: the value of the Nottingham Prognostic Index for patients treated in a single institution. Surg Today 2005;35:907-11. (Pubitemid 41540057)
12. Clark GM. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 1994;30:117-26. (Pubitemid 24242662)
13. Carter CL, Allen C, Henderson DE. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7. (Pubitemid 19032001)
14. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36. (Pubitemid 34983222)
15. Nemoto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980;45:2917-24. (Pubitemid 11191732)
16. Crump M, Goss PE, Prince M, et al. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996;14:66-9. (Pubitemid 26019998)
17. Diab SG, Hilsenbeck SG, de Moor C, et al. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 1998;16:1655-60. (Pubitemid 28234706)
18. Fountzilas G, Nicolaides C, Aravantinos G, et al. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study. Oncology 1998;55:508-12. (Pubitemid 28479106)
19. Anttinen J, Kautiainen H, Kuopio T. Role of mammography screening as a predictor of survival in postmenopausal breast cancer patients. Br J Cancer 2006;94:147-51. (Pubitemid 43088555)
20. Shen Y, Yang Y, Inoue LY, et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005;97:1195-203. (Pubitemid 41258225)
21. Hanrahan EO, Valero V, Gonzalez-Angulo AM, et al. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a, bN0M0): a review of the literature. J Clin Oncol 2006;24:2113-22. (Pubitemid 46628472)
22. Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006;7:983-90. (Pubitemid 44804136)
23. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
24. Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27:219-26.
25. Macmillan RD, Barbera D, Hadjiminas DJ, et al. Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. Results of a prospective comparison study. Eur J Cancer 2001;37:1076-80.
26. Blamey RW, Hornmark-Stenstam B, Ball G, et al. ONCOPOOL - a European database for 16,944 cases of breast cancer. Eur J Cancer 2010;46:56-71.
27. Smith JA 3rd, Gamez-Araujo JJ, Gallager HS, et al. Carcinoma of the breast: analysis of total lymph node involvement versus level of metastasis. Cancer 1977;39:527-32. (Pubitemid 8063513)
28. Megale Costa LJ, Soares HP, Gaspar HA, et al. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004;27:304-6. (Pubitemid 38737808)
29. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) breast cancer study group. Lancet 1990;335:1565-8.
30. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65. (Pubitemid 46606270)
31. Peparini N, Chirletti P. Lymph node ratio, number of excised nodes and sentinelnode concepts in breast cancer. Breast Cancer Res Treat 2011;126:829-33.
32. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomark Prev 2002;11:601-7. (Pubitemid 34760817)
33. Michaelson JS, Silverstein M, Sgroi D, et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003;98:2133-43. (Pubitemid 37392416)
34. Quiet CA, Ferguson DJ, Weichselbaum RR, et al. Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes. J Clin Oncol 1996;14:3105-11. (Pubitemid 26408803)
35. Mittendorf EA, Hunt KK, Boughey JC, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 2012;255:109-15.
36. Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 2010;12:R1.
37. Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 2010;28:99-104.
38. Rakha EA, Gandhi N, Climent F, et al. Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. Am J Surg Pathol 2011;35:1093-103.
39. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
40. Cardoso F, Van't Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008;26:729-35. (Pubitemid 351264385)
41. Rakha EA, Ellis IO. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol 2011;18:255-67.
42. Olivotto IA, Chua B, Elliott EA, et al. A clinical trial of breast radiation therapy versus breast plus regional radiation therapy in early-stage breast cancer: the MA20 trial. Clin Breast Cancer 2003;4:361-3. (Pubitemid 38139592)